US2.ai raised $15 M in Series A to automate battle against cardiovascular disease
Us2.ai, a Singapore-based medtech company that utilises machine learning to automate the battle against heart disease, has secured $15 million in a Series A round headed by IHH Healthcare and Heal Partners, an Australian healthcare-focused firm.
Lifesciences-focused Sequoia India, EDBI, and Partech Ventures, among others, joined Pappas Capital and current investors in the round.
The money will be used to help the company meet its clinical implementation growth objectives in the United States, Europe, and Asia. Furthermore, US2.ai intends to extend its commercial activities by partnering with prominent pharmaceutical firms, research institutes, and imaging suppliers throughout the world.
“Our focus has been to create a comprehensive solution beyond the existing industry standard of partial automation requiring manual intervention and providing limited measurements,” said James Hare, CEO and co-founder of Us2.ai. “Our software automatically processes full echocardiographic studies of 2D and Doppler images from any vendor in less than two minutes. It thus delivers complete echo reports, with fully explainable measurements, editable annotations and conclusions for every heart chamber.”
Clinical decision making and cardiovascular research for clinical trials employing echocardiography, the safest cardiac imaging modality, are improved with Us2.ai’s software tools. It brings together institutions and imaging laboratories from all around the world on a platform of ready-to-use automated tools for view categorization, segmentation, and federated learning across a variety of anonymized patient and disease cohorts.
Its product Us2.v1 includes automated measures such as 2D (cardiac volumes in all four chambers of the heart), M-mode (e.g., tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements), and tissue Doppler. They’ve covered the majority of the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography’s adult transthoracic echocardiography standard measures.
Fully automated Us2.v1 measures were totally interchangeable with expert human measurements and completely repeatable for each patient study.
Us2.ai has completed a number of initiatives with global pharmaceutical partners, including a ground-breaking approval study at Brigham and Women’s Hospital.
